Pharmacokinetics and pharmacodynamics
tumour
TUMOUR
Plasma concentration profiles on C1D1 and C1D15 are shown in Fig. Arithmetic mean (SD) concentration-time profiles following administration of LXS196 on cycle 1 day 1 and cycle 1 day 15 following multiple oral doses LXS196 reduced pMARCKS and phosphorylated PKC delta (pPKC delta), suggesting target engagement in on-treatment tumour biopsies. Reduction in pPKC delta in PBMCs was observed within 6 h post-dose at all dose levels (Fig. 